Ambrisentan therapy in pulmonary hypertension: clinical use and tolerability in a referral centre

Conclusion:
Ambrisentan is used as an initial therapy and as monotherapy in a minority of patients in a large UK PH referral centre. Discontinuation due to side effects, and especially oedema, was higher than reported in previous studies while discontinuation due to abnormal LFTs was very uncommon. A majority of patients who discontinued therapy due to side effects also previously or subsequently discontinued other PAH therapies. Improvement in WHO functional class was associated with superior survival.

Source: Therapeutic Advances in Respiratory Disease - June 5, 2014 Category: Respiratory Medicine Authors: Condliffe, R., Elliot, C. A., Hurdman, J., Sabroe, I., Billings, C., Kiely, D. G., Hamilton, N. Tags: Original Research Source Type: research